Cargando…

Antipsychotics dosage and antiparkinsonian prescriptions

BACKGROUND: To study the link between the dosage of several antipsychotics and the prescription of antiparkinsonians in an observational study. METHODS: In the context of a national naturalistic prospective observational study, a database containing all the prescriptions from 100 French psychiatrist...

Descripción completa

Detalles Bibliográficos
Autores principales: Acquaviva, Eric, Gasquet, Isabelle, Falissard, Bruno
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014748/
https://www.ncbi.nlm.nih.gov/pubmed/17767708
http://dx.doi.org/10.1186/1745-0179-3-14
_version_ 1782136559054618624
author Acquaviva, Eric
Gasquet, Isabelle
Falissard, Bruno
author_facet Acquaviva, Eric
Gasquet, Isabelle
Falissard, Bruno
author_sort Acquaviva, Eric
collection PubMed
description BACKGROUND: To study the link between the dosage of several antipsychotics and the prescription of antiparkinsonians in an observational study. METHODS: In the context of a national naturalistic prospective observational study, a database containing all the prescriptions from 100 French psychiatrists during the year 2002 was analysed. The inclusion criteria were a diagnosis of schizophrenia or schizoaffective disorder and age over 18. The mean dosage of antipsychotics with and without antiparkinsonians was compared. Since there were multiple prescriptions for a given subject, generalised mixed linear models were also used to study the link between antiparkinsonian prescription and antipsychotic dosage. RESULTS: antiparkinsonians were prescribed to 32,9% of the patients. Two groups of antipsychotics were observed relating to differences in dosage when an antiparkinsonian was co prescribed or not : a first group, where the mean dosage was higher with antiparkinsonians (risperidone, amisulpride and haloperidol) and a second group (clozapine, olanzapine), in which antiparkinsonian co prescription was not related to the dosage of antipsychotics. CONCLUSION: As a conclusion, it can be said that it is important to consider the dosage and the type of antipsychotic in the treatment of patients suffering of schizophrenia, because neurological side effects are frequent and can impair quality of life. Moreover the prescription of antiparkinsonians can lead to different side effects such anticholinergic effects.
format Text
id pubmed-2014748
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-20147482007-10-11 Antipsychotics dosage and antiparkinsonian prescriptions Acquaviva, Eric Gasquet, Isabelle Falissard, Bruno Clin Pract Epidemiol Ment Health Research BACKGROUND: To study the link between the dosage of several antipsychotics and the prescription of antiparkinsonians in an observational study. METHODS: In the context of a national naturalistic prospective observational study, a database containing all the prescriptions from 100 French psychiatrists during the year 2002 was analysed. The inclusion criteria were a diagnosis of schizophrenia or schizoaffective disorder and age over 18. The mean dosage of antipsychotics with and without antiparkinsonians was compared. Since there were multiple prescriptions for a given subject, generalised mixed linear models were also used to study the link between antiparkinsonian prescription and antipsychotic dosage. RESULTS: antiparkinsonians were prescribed to 32,9% of the patients. Two groups of antipsychotics were observed relating to differences in dosage when an antiparkinsonian was co prescribed or not : a first group, where the mean dosage was higher with antiparkinsonians (risperidone, amisulpride and haloperidol) and a second group (clozapine, olanzapine), in which antiparkinsonian co prescription was not related to the dosage of antipsychotics. CONCLUSION: As a conclusion, it can be said that it is important to consider the dosage and the type of antipsychotic in the treatment of patients suffering of schizophrenia, because neurological side effects are frequent and can impair quality of life. Moreover the prescription of antiparkinsonians can lead to different side effects such anticholinergic effects. BioMed Central 2007-09-03 /pmc/articles/PMC2014748/ /pubmed/17767708 http://dx.doi.org/10.1186/1745-0179-3-14 Text en Copyright ©2007 Acquaviva et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Acquaviva, Eric
Gasquet, Isabelle
Falissard, Bruno
Antipsychotics dosage and antiparkinsonian prescriptions
title Antipsychotics dosage and antiparkinsonian prescriptions
title_full Antipsychotics dosage and antiparkinsonian prescriptions
title_fullStr Antipsychotics dosage and antiparkinsonian prescriptions
title_full_unstemmed Antipsychotics dosage and antiparkinsonian prescriptions
title_short Antipsychotics dosage and antiparkinsonian prescriptions
title_sort antipsychotics dosage and antiparkinsonian prescriptions
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014748/
https://www.ncbi.nlm.nih.gov/pubmed/17767708
http://dx.doi.org/10.1186/1745-0179-3-14
work_keys_str_mv AT acquavivaeric antipsychoticsdosageandantiparkinsonianprescriptions
AT gasquetisabelle antipsychoticsdosageandantiparkinsonianprescriptions
AT falissardbruno antipsychoticsdosageandantiparkinsonianprescriptions